Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four ...
PharmExec13h
Emerging Biopharma Launches: Strategizing in Today’s Global Market
John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...